Welcome to our dedicated page for West Pharm Svcs SEC filings (Ticker: WST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
West Pharmaceutical Services, Inc. filings document the regulatory record of a Pennsylvania operating company that supplies injectable drug containment, delivery and contract-manufacturing services. Its Form 8-K reports commonly furnish quarterly and full-year operating results, financial presentation materials and Regulation FD disclosures tied to earnings releases.
West's proxy and annual meeting filings cover board elections, executive compensation, advisory votes and shareholder voting results for its common stock. Other current reports record executive-transition matters and related governance disclosures, while exhibit filings provide the formal press releases, presentations and Inline XBRL cover-page data attached to those events.
Joseph Molly reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services director Molly Joseph received a grant of 791 shares of common stock as restricted stock units. The award was granted at a price of $0.00 per share, reflecting equity compensation rather than an open-market purchase. After this grant, Joseph holds a total of 4,398.187 shares of West Pharmaceutical common stock. According to the disclosure, these restricted stock units will vest in full on the date of the next annual shareholder meeting, at which point they are expected to become fully owned shares, subject to any applicable plan terms.
HAUGEN JANET BRUTSCHEA reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services director Janet Brutschea Haugen received an equity award in the form of restricted stock units. She was granted 791 shares of common stock at no cash cost, increasing her directly held stake to 2,372.752 shares. The restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributed under the company’s Deferred Compensation Plan for Outside Directors, tying part of her compensation to future company performance.
FRIEL ROBERT F reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services director Robert F. Friel received a grant of 791 shares of common stock in the form of restricted stock units. The award carried a price of $0.00 per share as it is a compensation grant rather than an open-market purchase.
The restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributed under the Deferred Compensation Plan for Outside Directors. Following this award, Friel directly holds 5,512.97 shares of West Pharmaceutical Services common stock.
Feehery William F reported acquisition or exercise transactions in this Form 4 filing.
WEST PHARMACEUTICAL SERVICES INC director William F. Feehery received an equity award of 791 shares of common stock in the form of restricted stock units. The award was granted at no cash price and increases his directly held position to 32,519.345 shares.
The restricted stock units will vest in full on the date of the next annual shareholder meeting and will then be distributable under the company’s Deferred Compensation Plan for Outside Directors. This reflects routine director compensation rather than an open-market purchase or sale.
BUTHMAN MARK A reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services Inc. director Mark A. Buthman received an equity award of 791 shares of common stock. The shares were granted at a price of $0.00 per share as a form of compensation, not an open-market purchase.
These shares are in the form of restricted stock units that will vest in full on the date of the next annual shareholder meeting. After this grant, Buthman directly holds a total of 44,308.5494 shares of West Pharmaceutical common stock.
West Pharmaceutical Services, Inc. reported results of its 2026 annual shareholder meeting held virtually on May 4, 2026. Shareholders elected eleven directors to serve until the 2027 meeting and approved, on a non-binding basis, compensation for named executive officers.
As of the February 27, 2026 record date, there were 72,081,610 common shares outstanding, and 66,193,322 shares, or 91.83%, were represented at the meeting. Shareholders also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the 2026 fiscal year and voted against a shareholder proposal seeking an Independent Board Chair Policy.
West Pharmaceutical Services Inc ownership disclosure: Vanguard Capital Management reports beneficial ownership of 5,397,791 shares of Common Stock, representing 7.48% of the class. The filing lists sole voting power for 714,505 shares and sole dispositive power for 5,397,791 shares. The filing is signed by Ashley Grim as Head of Global Fund Administration.
West Pharmaceutical Services Inc ownership disclosure: Vanguard Portfolio Management reports beneficial ownership of 4,102,674 shares of Common Stock, representing 5.69% of the class as of 03/31/2026. Vanguard Portfolio Management indicates sole dispositive power over 4,102,674 shares and sole voting power over 8,665 shares. The filing describes holdings managed across Vanguard affiliates and notes the ownership reflects securities held by Vanguard funds and client accounts.
West Pharmaceutical Services senior vice president and chief HR officer Annette F. Favorite exercised stock options and sold shares of common stock. On April 27, she exercised options to acquire 2,817 shares at $83.47 per share and then sold 2,817 shares in an open-market transaction at a weighted average price of $305.2018 per share.
After these transactions, she directly holds 16,828.4906 shares of common stock and indirectly holds 4,966.6170 shares through a Non-Qualified Deferred Compensation Plan, showing she retains a meaningful equity stake in the company despite the net sale.
West Pharmaceutical Services VP and Chief Accounting Officer Chad Winters exercised stock options for 896 shares of common stock at $173.22 per share and on the same day sold 896 shares in an open-market sale at a weighted average price of $300.6688. After these transactions, he directly holds 1,522.81 shares.